Severe acute respiratory syndrome

Delta Variant Testing Device Developed by UAT Group Affiliate, Bacter Scientific

Retrieved on: 
Thursday, July 22, 2021

Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.

Key Points: 
  • Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.
  • Novi is the only hand-held, portable, battery powered device with built-in redundancy, delivering the most accurate results of any testing device.
  • A US government SARS-CoV-2 Interagency Group (SIG) developed Variant Classifications that defines three classes of SARS-CoV-2 variants.
  • Bacter Scientific does not assume the obligation to update any forward-looking statement, except as required by applicable law.

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers

Retrieved on: 
Wednesday, July 21, 2021

This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.

Key Points: 
  • This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.
  • These patients, called COVID-19 "long haulers," report lingering shortness of breath, cough, fatigue, and mental fog for months after recovery, impairing their return to work and everyday life.
  • Even by the lowest health care industry estimates, the magnitude of this secondary health crisis of COVID-19 long haulers will result in millions of affected individuals.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Energy Cloud Hummingbird™ Air Purification System Eradicates 99.5% or Greater of Airborne COVID-19 Virus on the First Pass

Retrieved on: 
Tuesday, July 20, 2021

Energy Cloud, a clean-tech company specializing in healthy buildings and energy efficient environments has a solution: Hummingbird EQ, an air purification system that captures and deactivates airborne COVID-19 virus.

Key Points: 
  • Energy Cloud, a clean-tech company specializing in healthy buildings and energy efficient environments has a solution: Hummingbird EQ, an air purification system that captures and deactivates airborne COVID-19 virus.
  • Hummingbird EQ was proven to capture and deactivate the airborne COVID-19 virus on the first airflow pass through the system by 99.5% or greater, reducing it to undetectable levels.
  • Unlike other air purification systems, Hummingbird does not release or produce any airborne chemicals as part of its inactivation of viruses.
  • The Hummingbird EQ is an air purification, indoor air quality monitoring and HVAC remote management system proven to deactivate 99.5% of SARS-CoV2 (COVID-19) delivering A+Air Quality.

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

Retrieved on: 
Tuesday, July 20, 2021

The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.

Key Points: 
  • The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.
  • The AMPIPROBE SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and AMPIPROBE SARS-CoV-2 Assay Kit for detection and analysis.
  • We are positioned to support rapid scale up and advance the new solutions in molecular testing that can address major challenges like COVID.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Retrieved on: 
Tuesday, July 20, 2021

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

EPA Adds Maryland, Nevada, Pennsylvania and Texas to Existing Public Health Emergency Exemption for Grignard Pure™ as Only Antiviral Air Treatment for Use Against COVID-19

Retrieved on: 
Monday, July 19, 2021

The additional Emergency Exemptions are approved for Maryland, Nevada, Pennsylvania and Texas, joining Georgia and Tennessee, which were approved on January 14, 2021.

Key Points: 
  • The additional Emergency Exemptions are approved for Maryland, Nevada, Pennsylvania and Texas, joining Georgia and Tennessee, which were approved on January 14, 2021.
  • Grignard Pure is the first and only EPA-approved antimicrobial air treatment solution designed to significantly reduce the viral load of the SARS-CoV-2 virus in the air, where transmission is most likely.
  • The EPA undertook a thorough review of the products health, safety, and efficacy performance, and confirmed Grignard Pures effectiveness in killing more than 98% of the SARS-CoV-2 virus.
  • To learn more about Grignard Pure, including access to safety and efficacy reports, visit GrignardPure.com or call 1 (855) 642-PURE (7873).

EPA Approves Mass Transit Air Treatment Solution for Texas, Nevada, Pennsylvania and Maryland

Retrieved on: 
Monday, July 19, 2021

Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.
  • Approved use sites in Texas, Nevada, Pennsylvania and Maryland include intrastate transportation.For a complete listing of approved use sites, please visit EPA's website .
  • Luminator's Renew Air Treatment System dispenses the antimicrobial air treatment through a connected, technologically advanced system that measures and automatically adjusts the amount of Grignard Pure that is dispensed.
  • "We know now with certainty that the virus is airborne, and an antimicrobial air treatment solution is needed to combat the virus particles.

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Retrieved on: 
Wednesday, July 14, 2021

Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.
  • The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19.
  • This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic, said Jan Verstreken, Hologics group president, International.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Retrieved on: 
Tuesday, July 13, 2021

Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.

Key Points: 
  • Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.
  • The CE Mark represents the second regulatory milestone for 8-gene Lung Cancer Assay, as it is already approved by Chinas NMPA and is being commercialized in China.
  • We are excited to receive the CE Mark, which represents an important new commercialization opportunity for our 8-gene Lung Cancer Assay.
  • Separately, the Company also reported comparative performance data of its SARS-CoV-2 RNA Test based on a SARS-CoV-2 reference panel established by the U.S. Food and Drug Administration (FDA).

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Retrieved on: 
Tuesday, July 13, 2021

Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.

Key Points: 
  • Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
  • In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California).
  • Seegene also said that it has successfully developed a research-use-only diagnostic tests, 'Allplex SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants.
  • According to Seegene, the combination use of its two assays including 'Allplex SARS-CoV-2 Variants II Assay' and the 'Allplex SARS-CoV-2 Variants I Assay' can screen almost all existing COVID-19 variants.